Table 4.
Extractable radioactivity following incubation of 200 ng/mL [14C]pyrotinib with human plasma, serum albumin, or α1-acid glycoprotein at 37°C for different amounts of time
| Time | Plasma | Serum albumin | α1-acid glycoprotein |
|---|---|---|---|
| (h) | ng eq./mL (%)a | ng eq./mL (%)a | ng eq./mL (%)a |
| 0 | 204 (102) | 202 (101) | 194 (97.2) |
| 2 | 195 (97.4) | 180 (90.0) | 165 (82.5) |
| 5 | 184 (91.8) | 170 (85.0) | 163 (81.5) |
| 8 | 139 (69.6) | 161 (80.5) | 157 (78.5) |
| 24 | 93.4 (46.7) | 123 (61.5) | 156 (78.0) |
apercentage of extractable radioactivity accounting for the radioactivity added into human plasma, serum albumin, or α1-acid glycoprotein